Filing Details

Accession Number:
0001209191-16-100468
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-02-19 16:13:06
Reporting Period:
2016-02-17
Filing Date:
2016-02-19
Accepted Time:
2016-02-19 16:13:06
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1510580 Kite Pharma Inc. KITE Biological Products, (No Disgnostic Substances) (2836) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1609644 F Rizwana Sproule C/O Kite Pharma, Inc.
2225 Colorado Avenue
Santa Monica CA 90404
Vp Regulatory Affairs No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-02-17 9,567 $1.35 18,308 No 4 M Direct
Common Stock Disposition 2016-02-17 9,467 $45.07 8,841 No 4 S Direct
Common Stock Disposition 2016-02-17 100 $46.01 8,741 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Disposition 2016-02-17 9,567 $0.00 9,567 $1.35
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
104,330 2024-03-24 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 31, 2015.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
  3. 25% of the 200,000 shares subject to the stock option vested and became exercisable on January 6, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.